Zacks.com on MSN6d
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...
Halozyme: Looking For More Growth Following Record Q3 Earnings
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Van ECK Associates Corp
Van ECK Associates Corp reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.5% in the 3rd quarter, according to the company in its most recent 13F filing with the ...
Zacks.com on MSN10d
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...
Halozyme Announces Record Earnings, Guidance
Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.
Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
Halozyme Therapeutics Inc (HALO) reports a 34% revenue increase, raises full-year guidance, and expands partnerships despite ...
Halozyme’s Robust Q3 2024 Performance and Promising Growth Outlook Justify Buy Rating
JMP Securities analyst Jason Butler has reiterated their bullish stance on HALO stock, giving a Buy rating yesterday. Jason Butler has given ...
bovnews13d
Halozyme Therapeutics, Inc. (HALO) Stock Sees Market Value Hit $6.41 billion: What Are the Implications?
On Thursday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $50.57 which represents a decrease of $-0.02 or -0.04% from the prior close of $50.59. The stock opened at $50.56 ...
bovnews13d
Halozyme Therapeutics (HALO): Unpacking the Surge in Stock Price
As of now, Halozyme’s stock has delivered a YTD performance of +36.82%, outpacing the S&P 500’s +19.62% return. This stark contrast not only showcases Halozyme’s exceptional growth but also emphasizes ...
Halozyme: Strong Buy Rating Backed by Robust Financial Performance and Promising Growth Catalysts
In a report released yesterday, Brendan Smith from TD Cowen maintained a Buy rating on Halozyme (HALO – Research Report), with a price ...
Halozyme Therapeutics Shares Climb As it Raises FY Outlook
Shares of Halozyme Therapeutics rose after the company reported earnings growth in the latest quarter and raised its outlook for the year. The stock was up 11% to $56.25 in post-market trading.
Benzinga.com2d
Halozyme Therapeutics (NASDAQ:HALO) Stock, Short Interest Report
Short interest in Halozyme Therapeutics Inc (NASDAQ:HALO) increased during the last reporting period, rising from 9.64M to 9.85M. This put 10.54% of the company's publicly available shares short.